PHARVARIS BV reports a Return on Equity (ROE) of -71.60%.

What is PHVS's dividend yield?

PHARVARIS BV offers a dividend yield of 0.00%.

What is PHVS's Quality Score?

Our AI rates PHVS's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PHVS?

Our AI Timing Score for PHVS is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PHVS belong to?

PHARVARIS BV is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

PHVS (NASDAQ) Stock Analysis | PHARVARIS BV

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

PHVS AI Analysis Summary

Our AI summary for PHVS: PHARVARIS BV (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -71.60%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PHVS

PHARVARIS BV

US:NASDAQ STOCK Healthcare >> Biotechnology News 91

USD 32.62

-1.26 (-3.72%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-71.6%

ROE

-65.1%

ROA

0.00%

Div Yield

PHARVARIS BV
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 32.62 Price -1.26 (-3.72%) Day Change	NEWS SCORE: 91

PHVS, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	91
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	32.62
PBV / Sector	10.02 / 5.20
Earning Per Share	-2.33

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	16.91 M GREAT
Average 1W Daily Value	12.04 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-65.13 / 27.02
ROA Average (%) / Sector	-48.06 / -368.17
ROA Change Average (%) / Sector	18.98 / 5,404.12 GOOD
ROE (%) / Sector	-71.60 / 3.47
ROE Average (%) / Sector	-52.78 / 6.51
ROE Change Average (%) / Sector	20.49 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:19
Symbol	PHVS
Name	PHARVARIS BV
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	69.88 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,367.53 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Grafenauweg 8, Zug, Switzerland, 6300

Phone: 31 712036410

Website: https://pharvaris.com

Employees: 134

Sector: Healthcare >> Biotechnology

Description: Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.